### 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

<table>
<thead>
<tr>
<th>Company</th>
<th>Address</th>
<th>Phone</th>
<th>Country</th>
<th>Phone Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pfizer Inc</td>
<td>Pfizer Pharmaceuticals Group</td>
<td>235 East 42nd Street</td>
<td>New York, New York 10017</td>
<td>1-212-573-2222</td>
</tr>
<tr>
<td>Pfizer Ltd, Pfizer Pharmaceuticals Group</td>
<td>Pfizer Ltd,</td>
<td>CT13 9NJ</td>
<td>United Kingdom</td>
<td>+00 44 (0)1304 616161</td>
</tr>
</tbody>
</table>

Material Name: Lymphocyte immune globulin, anti-thymocyte globulin (equine) sterile solution

Trade Name: Atgam Sterile Solution

Chemical Family: Mixture

Intended Use: Pharmaceutical product used as immunosuppressive agent

### 2. COMPOSITION/INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS List</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lymphocyte immune globulin, anti-thymocyte globulin (equine)</td>
<td>Not assigned</td>
<td>Not listed</td>
<td>5</td>
</tr>
<tr>
<td>Hydrochloric Acid</td>
<td>7647-01-0</td>
<td>231-595-7</td>
<td>**</td>
</tr>
<tr>
<td>Sodium hydroxide</td>
<td>1310-73-2</td>
<td>215-185-5</td>
<td>**</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS List</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glycine</td>
<td>56-40-6</td>
<td>200-272-2</td>
<td>*</td>
</tr>
<tr>
<td>Water for Injection</td>
<td>7732-18-5</td>
<td>231-791-2</td>
<td>*</td>
</tr>
</tbody>
</table>

Additional Information:
- * Proprietary
- ** to adjust pH

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

### 3. HAZARDS IDENTIFICATION

**Appearance:** Pink or brown sterile solution

**Signal Word:** DANGER

**Statement of Hazard:** Suspected of damaging the unborn child. Causes damage to immune system.

**Additional Hazard Information:**
- **Short Term:** May cause irritation: skin, eye (based on components) May produce allergic reactions after systemic administration.

**Known Clinical Effects:** Adverse effects most commonly reported in clinical use include fever, chills, skin reaction, blood cell changes, systemic toxicity. Serious allergic reactions, including anaphylaxis, have been reported.

**EU Indication of danger:** Toxic to Reproduction; Category 3

**EU Hazard Symbols:**
EU Risk Phrases: R63 - Possible risk of harm to the unborn child.

Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

4. FIRST AID MEASURES

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: Not applicable

Fire Fighting Procedures: During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

Fire / Explosion Hazards: Not applicable

6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions: Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

Measures for Environmental Protections: Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE
General Handling: Prevent inhalation, contact with eye, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Use adequate ventilation. Wash thoroughly after handling.

Storage Conditions: Store in a cool, dry place away from light. Keep refrigerated.

Storage Temperature: 2 - 8 °C

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Hydrochloric Acid
ACGIH Ceiling Threshold Limit: 2 ppm Ceiling
Australia PEAK = 5 ppm Peak
Australia PEAK = 7.5 mg/m³ Peak

Sodium hydroxide
OSHA - Final PELS - TWAs: 2 mg/m³
ACGIH Ceiling Threshold Limit: = 2 mg/m³ Ceiling
Australia PEAK = 2 mg/m³ Peak

Analytical Method: No method available.

Engineering Controls: Engineering controls should be used as the primary means to control exposures.

Personal Protective Equipment:
- Hands: Wear impervious gloves if skin contact is possible.
- Eyes: Safety glasses or goggles
- Skin: Use protective clothing (uniforms, lab coats, disposable coveralls, etc.) in both production and laboratory areas.
- Respiratory protection: If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES:

Physical State: Sterile solution
Molecular Formula: Mixture
Solubility: Soluble: Water

Color: Pink to brown
Molecular Weight: Mixture

10. STABILITY AND REACTIVITY

Stability: Stable under normal conditions of use.
Conditions to Avoid: Exposure to light.
Incompatible Materials: As a precautionary measure, keep away from strong oxidizers.

11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the individual ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)
MATERIAL SAFETY DATA SHEET

Material Name: Lymphocyte immune globulin, anti-thymocyte globulin (equine) sterile solution
Revision date: 04-Jan-2007

1. CHEMICAL IDENTIFICATION

Material Name: Lymphocyte immune globulin, anti-thymocyte globulin (equine) sterile solution

2. HAZARDS IDENTIFICATION

Irritation / Sensitization: (Study Type, Species, Severity)

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Carcinogen Status:
None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA. See below

Hydrochloric Acid
IARC: Group 3

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties of the formulation have not been thoroughly investigated. Releases to the environment should be avoided.
### 13. DISPOSAL CONSIDERATIONS

**Disposal Procedures:** Dispose of waste in accordance with all applicable laws and regulations.

### 14. TRANSPORT INFORMATION

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

### 15. REGULATORY INFORMATION

**EU Symbol:** Xn  
**EU Indication of danger:** Toxic to Reproduction; Category 3  
**EU Risk Phrases:** R63 - Possible risk of harm to the unborn child.  
**EU Safety Phrases:** S36/37 - Wear suitable protective clothing and gloves. S53 - Avoid exposure - obtain special instructions before use.

**OSHA Label:** DANGER  
Suspected of damaging the unborn child. Causes damage to immune system.

**Canada - WHMIS: Classifications**

**WHMIS hazard class:** Class D, Division 2, Subdivision A

**Hydrochloric Acid**

- **CERCLA/SARA 313 Emission reporting**
  - = 1.0 % de minimis concentration acid aerosols including mists, vapors, gas, fog, and other airborne forms of any particle size
- **CERCLA/SARA Hazardous Substances and their Reportable Quantities:**
  - = 2270 kg final RQ
  - = 5000 lb final RQ
- **CERCLA/SARA - Section 302 Extremely Hazardous TPQs**
  - = 500 lb TPQ gas only
- **CERCLA/SARA - Section 302 Extremely Hazardous Substances EPCRA RQs**
  - = 5000 lb EPCRA RQ gas only
- **Inventory - United States TSCA - Sect. 8(b)**
  - T
- **Australia (AICS):** Present
- **Standard for the Uniform Scheduling for Drugs and Poisons:** Schedule 5  
Schedule 6  
**EU EINECS List**

231-595-7
16. OTHER INFORMATION

Reasons for Revision: Corrected Section 1.

Prepared by: Toxicology and Hazard Communication
             Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied.

End of Safety Data Sheet